Globenewswire·2026-03-12 13:00Core Insights - Trinity Biotech has initiated the commercial rollout of its updated laboratory blood glucose monitoring solution in Brazil, specifically the next-generation HbA1c column system for its Premier Hb9210™ platform, following local regulatory approval [1][2] Company Developments - The upgraded boronate affinity column system has been introduced in Brazil, a significant market for diabetes management, which has one of the largest diabetes populations globally, estimated at approximately 16 to 18 million adults [2][4] - The Premier Hb9210™ platform has achieved the prestigious International Federation of Clinical Chemistry (IFCC) "Gold" classification for 2026, marking it as the only HbA1c system worldwide to receive this recognition, which highlights its clinical accuracy and precision [2][3] - Bruna Gigliotti has been appointed to lead the local Brazilian commercial organization, enhancing the company's market execution in anticipation of increased adoption of the Premier Hb9210™ platform [6] Market Context - Brazil's diabetes prevalence is on the rise, necessitating reliable and high-specificity HbA1c testing technologies to support effective diabetes management [4] - The boronate affinity technology used in the Premier Hb9210™ offers advantages in Brazil's diverse population, as it is less affected by haemoglobin variants, thereby improving patient outcomes and clinician confidence [5]